Price movement over the last 24 hours
Agilent Technologies Inc vs TJX Companies Inc — how do they compare? Agilent Technologies Inc trades at $128.71 (market cap $37.04B), while TJX Companies Inc trades at $153.26 (market cap $170.25B). The key difference: TJX Companies Inc is far larger — about 4.6× Agilent Technologies Inc's market cap, and TJX Companies Inc pays the higher dividend (1.25%). Which is the better fit depends on your goals.
| A | TJX | |
|---|---|---|
Market Cap | $37.04B | $170.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $168.41 |
52-Week Low | $110.24 | $121.35 |
Enterprise Value | $38.59B | $178.85B |
Dividend Yield | 0.78% | 1.25% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
TJX trades at $154.11, up slightly by 0.02% today, with a bearish technical signal from moving averages but strong fundamental performance. The company reported consistent earnings beats, with Q1 2026 EPS of $1.19 surpassing the $1.02 estimate, and maintains robust profitability with a 61.25% ROE. Revenue growth is steady, reaching $56.36B in 2025, supported by expansion in home goods and international markets.
Outlook remains positive with an 88% analyst buy rating and a $181.80 consensus price target, implying 18% upside. Risks include high valuation multiples like a 29.44 P/E and economic sensitivity, but strong cash flow and dividend payments provide stability. Investors should monitor Q2 2026 earnings for continued momentum.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →